Physician profile
Jun Ho Kim
NPI 1225444664
$13,155.09
in general payments reported to CMS, 2019-2025
12 companies · $11K in 2025
The $11K reported for 2025 was more than what 91% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $15.47 · 2021: $83.35 · 2022: $26.58 · 2023: $1,795 · 2024: $155 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,563 · Travel and Lodging: $2,625 · Food and Beverage: $1,504 · Education: $13.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,563.00 |
| Travel and Lodging | $2,624.78 |
| Food and Beverage | $1,503.67 |
| Education | $13.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sarepta Therapeutics, INC. | $8,865.42 | 2021-2025 | Elevidys |
| Biogen, INC. | $1,933.10 | 2019-2025 | |
| Genentech, INC. | $1,836.46 | 2022-2025 | Evrysdi |
| Inari Medical, INC. | $187.83 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| F. Hoffmann-La Roche Ag | $150.00 | 2025 | |
| Genentech USA, INC. | $43.67 | 2023 | Evrysdi |
| Depuy Synthes Sales INC. | $33.34 | 2021 | |
| Mallinckrodt Enterprises LLC | $31.14 | 2019 | |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $31.07 | 2019 | |
| Neurelis, INC. | $18.44 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $13.49 | 2024 | |
| Biomarin Pharmaceutical INC. | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jun Ho Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.